4 research outputs found
Recommended from our members
Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry.
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to help guide clinicians in balancing bleeding and thrombotic risks in these patients. HYPOTHESIS: Antithrombotic regimen prescriptions for AF patients undergoing PCI evolved after the publication of the 2016 CCS AF guidelines. METHODS: A prospective cohort of AF patients undergoing PCI with placement of a coronary stent from a single tertiary academic center was analyzed for the recommended antithrombotic regimen at discharge. Prescribing behavior was compared between three time periods (Cohort A [2010-2011]; Cohort B [2014-2015]; Cohort C [2017]) using the Ï2 test. In addition, antithrombotic management in Cohorts B and C were compared to guideline-recommended therapy. RESULTS: A total of 459 patients with AF undergoing PCI were identified. Clinical and procedural characteristics were similar between cohorts, with the exception of an increase in drug-eluting stent (DES) use over time (P <â.01). Overall, the rate of oral anticoagulation (OAC) increased over time (P <â.01), associated with an increase in nonvitamin K OAC prescription (P <â.01) and a concomitant decrease in vitamin K antagonist prescription (P <â.01). Despite this, the overall rate of anticoagulation remains below what would be predicted with perfect guideline compliance (75% vs 94%, P <â.01). CONCLUSION: There has been a dramatic shift in clinical practice for AF patients requiring PCI, with increases in prescription of OAC even in the context of an increase in the use of DES. However, room for further practice optimization still exists
Characterization of a plastic scintillating detector for the Small Animal Radiation Research Platform ( SARRP
The Canadian Womenâs Heart Health Alliance ATLAS on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women â Chapter 9: Summary of Current Status, Challenges, Opportunities, and Recommendations
This final chapter of the Canadian Womenâs Heart Health Alliance âATLAS on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Womenâ presents ATLAS highlights from the perspective of current status, challenges, and opportunities in cardiovascular care for women. We conclude with 12 specific recommendations for actionable next steps to further the existing progress that has been made in addressing these knowledge gaps by tackling the remaining outstanding disparities in womenâs cardiovascular care, with the goal to improve outcomes for women in Canada. RĂ©sumĂ©: Dans ce chapitre final de lâATLAS sur lâĂ©pidĂ©miologie, le diagnostic et la prise en charge de la maladie cardiovasculaire chez les femmes de lâAlliance canadienne de santĂ© cardiaque pour les femmes, nous prĂ©sentons les points saillants de lâATLAS au sujet de lâĂ©tat actuel des soins cardiovasculaires offerts aux femmes, ainsi que des dĂ©fis et des occasions dans ce domaine. Nous concluons par 12 recommandations concrĂštes sur les prochaines Ă©tapes Ă entreprendre pour donner suite aux progrĂšs dĂ©jĂ rĂ©alisĂ©s afin de combler les lacunes dans les connaissances, en sâattaquant aux disparitĂ©s qui subsistent dans les soins cardiovasculaires prodiguĂ©s aux femmes, dans le but dâamĂ©liorer les rĂ©sultats de santĂ© des femmes au Canada